Bevacizumab in treatment of high-risk ovarian cancer--a cost-effectiveness analysis

Journal article

Peer reviewed

J. K. Chan, T. J. Herzog, L. Hu, Bradley J. Monk, T. Kiet, K. Blansit, D. S. Kapp and X. Yu

Oncologist, Vol.19(5), pp.523-527

2014

PMID: 24721817

Metrics

5 Record Views

Title: Bevacizumab in treatment of high-risk ovarian cancer--a cost-effectiveness analysis
Creators: J. K. Chan (Author)
T. J. Herzog (Author)
L. Hu (Author)
Bradley J. Monk (Author) - Creighton University
T. Kiet (Author)
K. Blansit (Author)
D. S. Kapp (Author)
X. Yu (Author)
Additional links: http://dx.doi.org/10.1634/theoncologist.2013-0322
Publication Details: Oncologist, Vol.19(5), pp.523-527
Publisher: United States
Number of pages: 523-527
Identifiers: 991005931000902656
Academic Unit: School of Medicine; Obstetrics & Gynecology
Language: English
Resource Type: Journal article